Risk Factors for Ebola Virus Persistence in Semen of Survivors in Liberia
Authors
Dyal, JonathanKofman, Aaron
Kollie, Jomah Z
Fankhauser, John
Orone, Romeo
Soka, Moses J
Glaybo, Uriah
Kiawu, Armah
Freeman, Edna
Giah, Giovanni
Tony, Henry D
Faikai, Mylene
Jawara, Mary
Kamara, Kuku
Kamara, Samuel
Flowers, Benjamin
Kromah, Mohammed L
Desamu-Thorpe, Rodel
Graziano, James
Brown, Shelley
Morales-Betoulle, Maria E
Cannon, Deborah L
Su, Kaihong
Linderman, Susanne L
Plucinski, Mateusz
Rogier, Eric
Bradbury, Richard S
Secor, W Evan
Bowden, Katherine E
Phillips, Christi
Carrington, Mary N
Park, Yeon-Hwa
Martin, Maureen P
Aguinaga, Maria Del Pilar
Mushi, Robert
Haberling, Dana L
Ervin, Elizabeth D
Klena, John D
Massaquoi, Moses
Nyenswah, Tolbert
Nichol, Stuart T
Chiriboga, David E
Williams, Desmond E
Hinrichs, Steven H
Ahmed, Rafi
Vonhm, Benjamin T
Rollin, Pierre E
Purpura, Lawrence J
Choi, Mary J
UMass Chan Affiliations
MedicineDocument Type
Journal ArticlePublication Date
2022-05-27
Metadata
Show full item recordAbstract
Background: Long-term persistence of Ebola virus (EBOV) in immunologically privileged sites has been implicated in recent outbreaks of Ebola virus disease (EVD) in Guinea and the Democratic Republic of Congo. This study was designed to understand how the acute course of EVD, convalescence, and host immune and genetic factors may play a role in prolonged viral persistence in semen. Methods: A cohort of 131 male EVD survivors in Liberia were enrolled in a case-case study. "Early clearers" were defined as those with 2 consecutive negative EBOV semen test results by real-time reverse-transcription polymerase chain reaction (rRT-PCR) ≥2 weeks apart within 1 year after discharge from the Ebola treatment unit or acute EVD. "Late clearers" had detectable EBOV RNA by rRT-PCR >1 year after discharge from the Ebola treatment unit or acute EVD. Retrospective histories of their EVD clinical course were collected by questionnaire, followed by complete physical examinations and blood work. Results: Compared with early clearers, late clearers were older (median, 42.5 years; P < .001) and experienced fewer severe clinical symptoms (median 2, P = .006). Late clearers had more lens opacifications (odds ratio, 3.9 [95% confidence interval, 1.1-13.3]; P = .03), after accounting for age, higher total serum immunoglobulin G3 (IgG3) titers (P = .005), and increased expression of the HLA-C*03:04 allele (0.14 [.02-.70]; P = .007). Conclusions: Older age, decreased illness severity, elevated total serum IgG3 and HLA-C*03:04 allele expression may be risk factors for the persistence of EBOV in the semen of EVD survivors. EBOV persistence in semen may also be associated with its persistence in other immunologically protected sites, such as the eye.Source
Dyal J, Kofman A, Kollie JZ, Fankhauser J, Orone R, Soka MJ, Glaybo U, Kiawu A, Freeman E, Giah G, Tony HD, Faikai M, Jawara M, Kamara K, Kamara S, Flowers B, Kromah ML, Desamu-Thorpe R, Graziano J, Brown S, Morales-Betoulle ME, Cannon DL, Su K, Linderman SL, Plucinski M, Rogier E, Bradbury RS, Secor WE, Bowden KE, Phillips C, Carrington MN, Park YH, Martin MP, Aguinaga MDP, Mushi R, Haberling DL, Ervin ED, Klena JD, Massaquoi M, Nyenswah T, Nichol ST, Chiriboga DE, Williams DE, Hinrichs SH, Ahmed R, Vonhm BT, Rollin PE, Purpura LJ, Choi MJ. Risk Factors for Ebola Virus Persistence in Semen of Survivors in Liberia. Clin Infect Dis. 2023 Feb 8;76(3):e849-e856. doi: 10.1093/cid/ciac424. PMID: 35639875; PMCID: PMC10169428.DOI
10.1093/cid/ciac424Permanent Link to this Item
http://hdl.handle.net/20.500.14038/53672PubMed ID
35639875Rights
Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2022. This work is written by (a) US Government employee(s) and is in the public domain in the US.ae974a485f413a2113503eed53cd6c53
10.1093/cid/ciac424
Scopus Count
Collections
The following license files are associated with this item: